See more news releases in: Health Care & Hospitals, Medical Pharmaceuticals, Clinical Trials & Medical Discoveries, Domestic Policy
Don't Blame the PSA Test for the 'Overtreatment' of Prostate Cancer
Early Detection Pays Off, as the PSA Test is to Men what the Mammogram is to Women
WASHINGTON, July 27 /PRNewswire-USNewswire/ -- A new report published in the July 26 issue of Archives of Internal Medicine claims many men who are diagnosed with prostate cancer undergo aggressive therapy, even when they have low PSA scores and low-risk disease, saying "these results underscore the fact that PSA level, the current biomarker, is not a sufficient basis for treatment decisions."
"When it comes to 'overtreatment,' the PSA test is not to blame – it's what happens next," said Skip Lockwood, ZERO's CEO. "Low-risk or not, many men choose to undergo aggressive treatment to eliminate the cancer from their bodies and their conscience, rather than simply monitoring the disease throughout their lives. Some doctors and patients are too quick to rush to treatment rather than carefully determine the risks and benefits of various procedures."
Plus, the proof is in the science – the PSA test saves lives. The authors of the new report even point out themselves "the tremendous improvement in survival has been attributed to early detection and treatment." Because of early detection, 90 percent of patients are diagnosed before the cancer spreads beyond the prostate and nearly 100 percent of those patients survive at least five years. The National Cancer Institute has acknowledged the PSA test cuts the prostate cancer mortality rate by nearly 50 percent, and the Goteborg (Sweden) Randomized Population-Based Prostate Cancer Screening Trial has shown the risk of over-diagnosis has been blown out of proportion for some time and is actually less than previously thought, with just 12 men needed to be diagnosed to save one man's life.
"Bottom line, the PSA test is to men what the mammogram is to women. Even with its inability to distinguish indolent prostate cancer from aggressive cases, the PSA test is till the best tool available today for detecting prostate cancer. So instead of pointing out its flaws, we should be working on ways to make it better," said Lockwood.
SOURCE ZERO - The Project to End Prostate Cancer
Back to top
RELATED LINKS
http://www.zerocancer.org
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
PR Newswire Membership
Fill out a PR Newswire membership form or contact us at (888) 776-0942.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.
Featured Video
More in These Categories
Journalists and Bloggers
![]()
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Free Investing Newsletter from Investor Uprising!
Learn to navigate the world's financial system and profit from leading companies.
Register for Investor Uprising, the people's investment site, for a free weekly newsletter, information, education and premium research including our latest IU Confidential Report - "All That Glitters: The Ultimate Gold Report".
- Site Preview
-
Close Site Preview
-
View FullScreen

